Trial Profile

A Phase II, Multi-center, Open-label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients With Brain Metastases.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel trevatide (Primary)
Indications Brain metastases; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms GRABM-L
Sponsors AngioChem

Most Recent Events

30 May 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
03 Dec 2012 Status changed from recruiting to discontinued.
14 Jun 2012 Additional lead trial investigator (Jeffrey J. Raizer) added as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com